Literature DB >> 21765107

25-hydroxyvitamin D levels and vitamin D deficiency in children with rheumatologic disorders and controls.

Christina F Pelajo1, Jorge M Lopez-Benitez, Laurie C Miller.   

Abstract

OBJECTIVE: To evaluate the prevalence of vitamin D deficiency, as well as factors associated with serum 25-hydroxyvitamin D [25(OH)D] levels, in children attending a pediatric rheumatology clinic, and to determine whether there was a difference in serum 25(OH)D levels and in vitamin D deficiency between children with autoimmune disorders and nonautoimmune conditions.
METHODS: Cross-sectional analysis of serum 25(OH)D levels of patients between the ages of 2 and 19 years, seen between November 2008 and October 2009.
RESULTS: A total of 254 patients were studied (169 autoimmune disorders, 85 nonautoimmune conditions). The mean age of study patients was 12.3 years; 67% were female and 80% were white. In the autoimmune disorders group, 23% had vitamin D deficiency [serum 25(OH)D < 20 ng/ml], and in the nonautoimmune conditions group 14% were vitamin D deficient. The average level of serum 25(OH)D was 28.6 (± 11) ng/ml (range 2 to 59). Age, ethnicity, body mass index, use of supplements, and season were significantly associated with serum levels of 25(OH)D (all p ≤ 0.02). The OR of patients with autoimmune disorders being vitamin D deficient was 2.3, in relation to patients with nonautoimmune conditions (p = 0.04).
CONCLUSION: Twenty percent of patients attending a pediatric rheumatology clinic were vitamin D deficient. Patients with autoimmune disorders were more likely to be vitamin D deficient than patients with nonautoimmune conditions. Screening of serum 25(OH)D levels should be performed for patients with autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765107     DOI: 10.3899/jrheum.110123

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  25-hydroxyvitamin D levels and juvenile idiopathic arthritis: is there an association with disease activity?

Authors:  Christina F Pelajo; Jorge M Lopez-Benitez; David M Kent; Lori Lyn Price; Laurie C Miller; Bess Dawson-Hughes
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

Review 2.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 3.  Long-term bone health in glucocorticoid-treated children with rheumatic diseases.

Authors:  Isabelle Rousseau-Nepton; Bianca Lang; Celia Rodd
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 4.  Vitamin D—update for the pediatric rheumatologists.

Authors:  Jelena Vojinovic; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2015-05-29       Impact factor: 3.054

5.  Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort.

Authors:  Claudia Sengler; Julian Zink; Jens Klotsche; Martina Niewerth; Ina Liedmann; Gerd Horneff; Christoph Kessel; Gerd Ganser; Angelika Thon; Johannes-Peter Haas; Anton Hospach; Frank Weller-Heinemann; Arnd Heiligenhaus; Dirk Foell; Angela Zink; Kirsten Minden
Journal:  Arthritis Res Ther       Date:  2018-12-13       Impact factor: 5.156

6.  Prevalence of Vitamin D Deficiency in Patients Treated for Juvenile Idiopathic Arthritis and Potential Role of Methotrexate: A Preliminary Study.

Authors:  Maciej K Stawicki; Paweł Abramowicz; Adrian Góralczyk; Justyna Młyńczyk; Anna Kondratiuk; Jerzy Konstantynowicz
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

7.  Vitamin D concentrations and disease activity in Moroccan children with juvenile idiopathic arthritis.

Authors:  Ilham Bouaddi; Samira Rostom; Dalal El Badri; Asmae Hassani; Bouchra Chkirate; Redoine Abouqal; Bouchra Amine; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2014-04-01       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.